Quince Therapeutics
Open
$1.30
Prev. Close
$1.31
High
$1.30
Low
$1.29
Market Snapshot
$6.85M
-0.1
-1.31
36
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
emptyResult
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. The company is headquartered in South San Francisco, California and currently employs 36 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Recently from Cashu
It seems like you forgot to include the content you want summarized. Please provide the text, and I’ll help you with a suitable title!
Please provide the content you would like me to summarize, and I will create the article for you.
Quince Therapeutics Advances Cell Therapy Innovations for Rare Disease Treatments
Quince Therapeutics Advances in Cell Therapy for Rare Diseases Quince Therapeutics, a biotechnology company specializing in developing innovative therapies for rare diseases, notably improves its stan…
Quince Therapeutics Advances Digital Therapeutics for Enhanced Chronic Disease Management and Patient Outcomes
Quince Therapeutics Moves Forward in Digital Therapeutics Development Quince Therapeutics is making significant strides in the field of digital therapeutics, emphasizing the integration of innovative…
Quince Therapeutics Pioneers Gene Therapy Advancements for Neurological Disorder Treatments
Quince Therapeutics Advances in Gene Therapy Approach for Neurological Disorders Quince Therapeutics makes significant strides in the field of gene therapy, focusing on innovative treatments for neuro…